Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Seborrheic Dermatitis Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult

NCT03830177
View directory record Official record
Conditions
Dermatitis, Seborrheic, Dry Skin; Eczema
Interventions
Natural Treatment
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04091646
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers

NCT01254162
View directory record Official record
Conditions
Oily Skin, Seborrhea
Interventions
MTC896 Gel
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Results available

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

NCT03567980
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Crisaborole
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 21, 2026, 10:21 PM EDT
Terminated Not applicable Interventional

Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation

NCT01315951
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Petroleum Jelly
Biological
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Burton, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Jul 21, 2026, 10:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurobiology of the Scalp in Seborrheic Dermatitis

NCT02349854
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Biopsy
Procedure
Lead sponsor
Boston University
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

NCT04973228
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam, Vehicle Foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
9 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • San Diego, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

NCT00403559
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Elidel, Ketoconazole Cream
Drug
Lead sponsor
Dermatology Specialists Research
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Seborrheic Dermatitis

NCT01703793
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Test Product 49778, Test Product 10156, Vehicle (placebo)
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Early Phase 1 Interventional

Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

NCT03114111
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
aminolevulinic acid (ALA), Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jul 21, 2026, 10:21 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cleansing Device for the Treatment of Scalp and Hair Conditions

NCT05319444
View directory record Official record
Conditions
Dandruff, Seborrheic Dermatitis, Hair Loss
Interventions
Off-brand Waterpik®
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 21, 2026, 10:21 PM EDT
Terminated Phase 2 Interventional

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

NCT06013371
View directory record Official record
Conditions
Seborrheic Dermatitis, Papulopustular Rosacea
Interventions
PF-07038124, Placebo Ointment
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ruxolitinib in Seborrheic Dermatitis

NCT05787860
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Ruxolitinib 1.5% Cream
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Results available

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04445987
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
ARQ-154
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
9 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Beverly Hills, California • Encino, California • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo

NCT01203189
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
ketoconazole 2% foam, ketoconazole 2% shampoo
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 21, 2026, 10:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis

NCT05942248
View directory record Official record
Conditions
Acne, Melasma, Rosacea, Seborrheic Dermatitis
Interventions
No Intervention
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease

NCT03582137
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Results available

Promiseb Topical Cream for Cradle Cap

NCT01214434
View directory record Official record
Conditions
Cradle Cap, Infantile Seborrheic Dermatitis
Interventions
Promiseb Topical Cream, Bland emollient
Device · Other
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
30 Days and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Norwich, Connecticut • Louisville, Kentucky • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 2 Interventional

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

NCT00991198
View directory record Official record
Conditions
Rosacea, Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis
Interventions
Topical oxygen, placebo
Drug
Lead sponsor
Aria Aesthetics Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 21, 2026, 10:21 PM EDT